Amplia

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Science

Contact

Board

Company Overview

Team

Corporate Governance

Corporate Directory

Values

Clinical Advisers

About Us

Video Updates

Presentations

In the News

Communication

Updates

US Shareholders

Investor FAQs

Shareholder Services

Research Reports

Reports

Announcements

Investor Fact Sheet

Top 20 Shareholders

Share Price

Investor Centre

Clinical Trial

Webinars

Home

Montserrat

Amplia Therapeutics Limited

upload.jpg

Amplia Therapeutics has achieved a key milestone in its ongoing Phase 1b/2a ACCENT trial, with 15 confirmed partial responses now recorded - sufficient to demonstrate that narmafotinib combined with chemotherapy is superior to chemotherapy alone in advanced pancreatic cancer patients.

The ACCENT trial is evaluating our best-in-class FAK inhibitor narmafotinib in combination with standard-of-care chemotherapies gemcitabine and Abraxane®. A confirmed partial response is a formal designation where tumour shrinkage >30% is recorded and sustained for two or more months with no new cancerous lesions detected.

Amplia CEO & MD, Dr Chris Burns, commented:

"We are extremely excited to have now recorded 15 confirmed partial responses in the ACCENT trial, demonstrating the benefit of adding narmafotinib to standard-of-care chemotherapy. With over 20 patients still on study we are hopeful that further PR's will be observed."

The Phase 2a ACCENT trial is fully recruited with top-line data expected in mid Q3 2025.

ACCENT Trial Data Demonstrates Narmafotinib + Chemotherapy Combination Superior To Chemotherapy Alone